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Abstract
Multiple genes (e.g., POMT1, POMT2, POMGnT1, ISPD, GTDC2, B3GALNT2, FKTN, FKRP, and LARGE) are
known to be involved in the glycosylation pathway of a-dystroglycan (a-DG). Mutations of these genes result in
muscular dystrophies with wide phenotypic variability. Abnormal glycosylation of a-DG with decreased ex-
tracellular ligand binding activity is a common biochemical feature of these genetic diseases. While it is known
that LARGE overexpression can compensate for defects in a few aforementioned genes, it is unclear whether it
can also rescue defects in FKRP function. We examined adeno-associated virus (AAV)-mediated LARGE or
FKRP overexpression in two dystrophic mouse models with loss-of-function mutations: (1) Largemyd (LARGE
gene) and (2) FKRPP448L (FKRP gene). The results agree with previous findings that overexpression of LARGE
can ameliorate the dystrophic phenotypes of Largemyd mice. In addition, LARGE overexpression in the
FKRPP448L mice effectively generated functional glycosylation (hyperglycosylation) of a-DG and improved
dystrophic pathologies in treated muscles. Conversely, FKRP transgene overexpression failed to rescue the
defect in glycosylation and improve the phenotypes of the Largemyd mice. Our findings suggest that AAV-
mediated LARGE gene therapy may still be a viable therapeutic strategy for dystroglycanopathies with FKRP
deficiency.
Introduction
Dystroglycanopathies are primary muscle diseaseslinked with progressive pathological changes in skeletal
muscle. The diseases are characterized by mutations in a
multitude of genes (e.g., POMT1, POMT2, POMGnT1,
ISPD, GTDC2, B3GALNT2, FKTN, FKRP, and LARGE) that
are associated with a broad spectrum of clinical and patho-
logical severity (Toda et al., 2000; Yoshida et al., 2001;
Beltrán-Valero de Bernabé et al., 2002; van Reeuwijk et al.,
2005; Roscioli et al., 2012; Ogawa et al., 2013; Stevens et al.,
2013). Specific to FKRP, mutations in the gene have been
reported to cause mild limb-girdle muscular dystrophy type
2I to severe congenital muscular dystrophies (CMD) such as
Walker–Warburg syndrome, muscle–eye–brain disease, or
CMD type 1C with or without central nervous system in-
volvement (Beltrán-Valero de Bernabé et al., 2004; Brown
et al., 2004; Mercuri et al., 2006). Exact mechanisms for the
variation in disease severity are not clearly understood, al-
though several factors, including the site of the mutations,
levels of gene expression, and genetic background, are con-
sidered important. The hallmark of all of these genetic mu-
tations is the disruption of the dystrophin–glycoprotein
complex (DGC).
The DGC is a multimeric transmembrane protein as-
semblage that provides a molecular link between the sub-
sarcolemmal cytoskeleton and the extracellular matrix
(Ervasti and Campbell, 1991, 1993). The exact function of
the DGC as a whole has yet to be completely determined;
however, it is deemed essential in contributing to the
structural stability of the muscle cell membrane during the
muscle contraction cycle (Campbell, 1995). In part, the in-
tegrity of muscle tissues is reliant on a central component
known as dystroglycan (DG)—a glycoprotein encoded by
the DAG1 gene that is posttranslationally cleaved into two
noncovalently associated subunits: a-DG (N-terminus) and
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b-DG (C-terminus) (Ervasti et al., 1990; Yoshida and
Ozawa, 1990; Ibraghimov-Beskrovnaya et al., 1992). Alpha-
DG is extracellular and binds to laminin in the basement
membrane, whereas b-DG is a transmembrane protein that
binds to dystrophin within the cytoplasm (Ibraghimov-
Beskrovnaya et al., 1992). Extensive posttranslational pro-
cessing (glycosylation) of a-DG is critical for linking the
DGC complex to extracellular matrix proteins (Gee et al.,
1994; Talts et al., 1999). Alpha-DG is both N- and O-linked
glycosylated, with only the O-linked glycans apparently
essential for muscle membrane integrity—removal of the O-
linked glycans eliminates the ligand binding capabilities
(Ervasti et al., 1990; Combs and Ervasti, 2005). The process
of creating ligand-binding glycan structures on a-DG is
critically dependent on the function of the aforementioned
genes that encode putative or known glycosyltransferases.
POMT1 and POMT2 catalyze the initial O-mannosylation
of proteins (Manya et al., 2004), while POMGnT1 acts as a
protein O-mannose b-1,2-N-acetylglucosaminyltransferase
(Yoshida et al., 2001). More recently, it was shown that
LARGE could act as a bifunctional glycosyltransferase
(xylosyltransferase and glucuronyltransferase activities)
producing repeating units of [–3-xylose–a1,3-glucuronic
acid-b1–] (Inamori et al., 2012). However, functions of both
FKTN and FKRP in the pathway of a-DG glycosylation
remain elusive, although they are likely to be involved in
postphosphoryl modifications of the O-mannose (Kuga
et al., 2012).
Among the known genes involved in glycosylation,
LARGE appears to possess some of the more unique
properties in the pathway of a-DG glycosylation. Early
studies reported that LARGE could modify complex N- and
mucine O-glycans on a-DG to induce laminin binding
(Patnaik and Stanley, 2005). LARGE overexpression com-
petes to modify GlcNAc terminals with galactosylation to
generate the functional glycans on both O-linked and N-
linked glycans (Hu et al., 2011). LARGE also facilitates
functional phosphoryl glycosylation of O-linked mannose
and N-linked glycans on proteins other than a-DG (Zhang
and Hu, 2012). The unique role LARGE plays in the gly-
cosylation of a-DG is further demonstrated by reports that
LARGE overexpression can bypass defects in glycosylation
of a-DG caused by mutations of FKTN, POMGnT1, and
POMT1 in cell culture systems and in POMGnT1 knockout
mouse models (Barresi et al., 2004; Yu et al., 2013). The
interaction between LARGE and FKRP on the glycosylation
of a-DG is not fully understood, and it is unclear whether
overexpression of LARGE can overcome the defects in
FKRP function and vice versa. In the current approach,
we utilize adeno-associated virus (AAV)-mediated over-
expression of LARGE and FKRP to investigate the func-
tional role of the two genes for their ability to rescue the
deficiency of the other.
Materials and Methods
Mouse models
Colonies of Largemyd and C57BL/6 (wild-type) mice
were originally obtained from the Jackson Laboratory (Bar
Harbor, ME). The wild-type mice were used as controls.
FKRPP448L knock-in mice were generated by inGenious
Targeting Laboratory (Stony Brook, NY). The targeting
vector was engineered with a c.1343C > T point mutation in
exon 3 of the mouse FKRP gene, resulting in an amino acid
change from proline-to-leucine at position 448 (P448L)
(Chan et al., 2010). A loxP/FRT-flanked neomycin phos-
photransferase (Neor) gene expression cassette was inserted
in intron 2 and subsequently removed in vivo by cross-
breeding with C57BL/6 Flp mice and further backcrossed to
C57BL/6 for 10 generations by inGenious Targeting La-
boratory to create the homozygote FKRPP448L mice. All
mice were housed in the vivarium of Carolinas Medical
Center (CMC) according to animal care guidelines of the
institute. All animal studies were approved by the Institu-
tional Animal Care and Use Committee of CMC.
Gene construction and AAV production
Full-length human LARGE1 cDNA was amplified from
human skeletal muscle tissue by RT-PCR. The 2320 bp
fragment containing the 5¢ NheI and 3¢ BglII was cloned
into pcDNA3.1/myc-His( - ) A (Life Technologies, Carlsbad,
CA). The resulting construct was named HL1/pcDNA3.1-
myc-His. For HL1/AAV production, the NheI/BglII frag-
ment was subcloned into AAV serotype 9 (AAV9) vector
under control of a chicken b-actin (CB) promoter and cy-
tomegalovirus (CMV) enhancer. The final construct was
named pXX-CB-LARGE-Myc (AAV9-LARGE in short)
(Supplementary Fig. S1; Supplementary Data are available
online at www.liebertpub.com/hum).
Full-length human FKRP cDNA was codon optimized
and synthesized for high expression in Mus musculus
(mouse) (GeneArt; Life Technologies). The Myc tag coding
sequence, N-EQKLISEEDL-C (1.2 kDa), was linked to the
C-terminus of the FKRP and a Kozak sequence was placed
at the N-terminus of the FKRP coding sequence. The syn-
thetic fragment was cloned into pMK-RQ (kanR) using SfiI
restriction sites. The resulting vector was named FKRP-
pMK-RQ (GeneArt; Life Technologies). The NotI-SalI
fragment of optimized FKRP-Myc was subcloned into the
same restriction enzyme sites of the AAV9 vector previ-
ously used for LARGE. The final construct was named
pXX-CB-FKRP-Myc (AAV9-FKRP in short) (Supplemen-
tary Fig. S1).
The recombinant AAV vector stocks were produced ac-
cording to the three-plasmid cotransfection method reported
previously (Xiao et al., 1998). The AAV vectors were
subsequently purified using a second-generation CsCl pro-
tocol that incorporates differential precipitation of AAV
particles by polyethylene glycol (Ayuso et al., 2010). Vector
titers were determined by both dot-blot and real-time PCR
methods using previously published protocols (Veldwijk
et al., 2002; Rohr et al., 2005). The concentration of viral
vectors was kept in the range of 2 · 1012 to 5 · 1012 vector
genomes/ml and stored at - 80C until future use.
Cell culture and vector delivery to dystrophic mice
C2C12 myoblast cells (ATCC CRL-1772) were grown in
Dulbecco’s modified Eagle’s medium (Gibco, Life Tech-
nologies) supplemented with 10% fetal bovine serum (FBS),
4 mM L-glutamine, and 100 lg/ml penicillin–streptomycin
in a 96-well plate (Greiner Bio-One, Monroe, NC). For
differentiation, cells were grown to about 90% confluence
and the growth medium was then replaced with Skeletal
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Muscle Cell Media (Cell Applications, San Diego, CA).
Two days after differentiation, AAV9-FKRP or AAV9-
LARGE (2 · 1010 vector genomes/ml) was added into the
culture medium to each 96-well, and continued culturing for
72 hr before harvesting. For Western blots, C2C12 cells
were cultured in T-25 flasks under the same culture condi-
tions, but infected with 5 · 1011 vector genomes/ml.
Largemyd mice were administered with AAV9-LARGE
(5 · 1010 vector genomes/ml) in phosphate-buffered saline
(PBS) via intramuscular injection into the tibialis anterior
muscle at the age of 3 months (n = 3); mice were sacrificed 1
week after injection. FKRPP448L mice were administered
with AAV9-LARGE at a dose of 4 · 1010 vector genomes
per gram body weight in PBS via a single intraperitoneal
injection at the age of 5 weeks (n = 3); mice were sacrificed
5 weeks after injection. Largemyd mice were administered
with AAV9-FKRP at a dose of 4 · 1010 vector genomes per
gram body weight in PBS via a single intraperitoneal in-
jection at the age of 3 months (n = 3); mice were sacrificed
5 weeks after injection. Untreated and wild-type control
mice were 12 weeks and 3 months old for FKRPP448L and
Largemyd cohorts, respectively. Blood and muscle samples
were collected and stored accordingly for future analysis.
Histology and cross-sectional area analysis
Skeletal and heart muscle tissues were dissected and
snap-frozen in liquid nitrogen-chilled isopentane. Tissues
were cryosectioned (5 lm thickness) and positioned on glass
microscope slides, and then stored at - 80C until future
use. Tissue sections were stained with hematoxylin and
eosin (H&E). Muscle cross-sectional fiber radii and per-
centage of myofibers with centrally located nuclei were
determined from tibialis anterior muscles stained with H&E.
Three random 20· magnification images per section per
animal were used. Images were visualized using an Olym-
pus BX51/BX52 fluorescence microscope (Opelco, Dulles,
VA) and captured using the Olympus DP70 Digital Camera
System (Opelco).
Antibodies
Antibodies used in this study were obtained as follows:
mouse monoclonal a-DG (clone IIH6C4) and rabbit poly-
clonal GM130 from EMD Millipore (Billerica, MA); mouse
monoclonal b-DG (7D11) and mouse monoclonal c-Myc
(9E10) from Developmental Studies Hybridoma Bank (Iowa
City, IA); rabbit polyclonal c-Myc and rabbit polyclonal
laminin from Sigma (St. Louis, MO); rat monoclonal la-
minin a2 from Enzo Life Sciences (Farmingdale, NY);
mouse monoclonal GM130-Alexa Fluor 488 from BD
Biosciences (San Jose, CA); goat polyclonal LARGE (Y-14)
from Santa Cruz Biotechnology (Dallas, TX); and rabbit
polyclonal FKRP-STEM was a gift from Dr. Derek J. Blake
(University of Oxford).
Immunohistochemical analysis
For the detection of LARGE, Myc tag, GM130, and
FKRP, frozen cryosections (5 lm thick) were initially fixed
with 4% paraformaldehyde for 12 min and then immediately
washed with PBS three times, each for 5 min. Sections were
blocked with 8% bovine serum albumin (BSA) and 10%
FBS diluted in PBS for 30 min. Sections were then incu-
bated with primary antibodies: LARGE (Y-14) (1:50); c-
Myc (9E10) (1:15) or c-Myc (1:250); GM130-Alexa Fluor
488 or GM130 (1:50); FKRP-STEM (1:2500). For the de-
tection of functionally glycosylated a-DG, frozen cryosec-
tions (5 lm thick) were initially fixed in a cold ( - 20C)
ethanol:acetic acid (1:1) mixture for 1 min and then imme-
diately washed with PBS four times, each for 15 min. Sec-
tions were blocked with 8% BSA in PBS for 30 min.
Sections were then incubated with the primary antibody:
IIH6C4 (1:200). For the detection of laminin, frozen cryo-
sections (5 lm thick) were initially washed with PBS. Sec-
tions were then blocked with 20% FBS/10% normal goat
serum diluted in PBS for 30 min. Sections were then incu-
bated with the primary antibody: laminin (1:60) or laminin
a2 (1:200). Antigoat IgG, antimouse IgG, antirabbit IgG,
antirat IgG, or antimouse IgM secondary antibodies tagged
with Alexa Fluor 488 or Alexa Fluor 594 (Life Technolo-
gies) were applied at various dilutions for 1 hr. Sections
were washed with PBS three times, each for 5 min, and
mounted with Fluorescence Mounting Medium (Dako,
Carpinteria, CA) containing 1 · DAPI (4¢,6-diamidino-2-
phenylindole). Similar procedures were used for the staining
of cultured cells. All steps were performed at room tem-
perature unless specified otherwise. Images were visualized
using an Olympus BX51/BX52 fluorescence microscope
(Opelco) and captured using the Olympus DP70 Digital
Camera System (Opelco). The percentage of IIH6C4-
positive fibers was determined from tibialis anterior mus-
cles. Three random 20· magnification images per section
per animal were used.
Immunoprecipitation
Antibody/Protein G binding. About 25 ll of c-Myc
(Sigma) was diluted in 200 ll PBS, incubated with Dyna-
beads Protein G (Life Technologies) for 1 hr at room tem-
perature, and subsequently washed with PBS. Protein lysate
was prepared with RIPA (Radio-IP Assay) buffer: 50 mM
Tris-HCl, 150 mM NaCl, 0.1% sodium dodecyl sulfate,
0.1% sodium deoxycholate, and 1% Triton X-100, supple-
mented with a protease inhibitor cocktail (Sigma). One
milligram of the cardiac muscle lysate in 500 ll volume
from AAV9-FKRP-treated FKRPP448L mice or controls was
incubated with the antibody/Protein G by swinging head-
over-tail for overnight at 4C. The mixture was then washed
three times with RIPA buffer. Precipitates of the complex
were then heated at 70C for 10 min in Novex Tris-Glycine
SDS (2 ·) (Life Technologies) and then subjected to Wes-
tern blot analysis.
Western blot analysis and laminin overlay assay
Protein extraction and Western blot analysis were per-
formed as reported previously (Chan et al., 2010). Initially,
total proteins were extracted from tissues via homogeniza-
tion in TX-100 buffer (1% Triton X-100; 50 mM Tris, pH
8.0; 150 mM NaCl; 0.1% sodium dodecyl sulfate) supple-
mented with protease inhibitor cocktail (Sigma). The su-
pernatants were collected by centrifugation at 18,000 · g
for 15 min at 4C. The clear lysates were then passed through
Zeba desalting columns (Pierce, Rockford, IL). Protein con-
centrations were determined by a DC protein assay (Bio-Rad,
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Hercules, CA). Protein samples were electrophoresed on a
4–20% Tris-Glycine gel (Life Technologies) at 200 mA for
3 hr and then transferred to an Immun-Blot polyvinylidene
difluoride (PVDF) membrane (Bio-Rad). For Western blot
analysis, the PVDF membranes were blocked with Protein-
Free T20 (TBS) Blocking Buffer (Pierce) overnight at 4C
and then incubated with primary antibodies—IIH6C4
(1:2000), b-DG (1:500), FKRP-STEM (1:20,000), or
LARGE (Y-14) (1:500)—in 20 mM Tris (pH 7.4), 150 mM
NaCl, 0.1% Tween 20, and 0.5% gelatin. Antigoat, anti-
mouse, or antirabbit HRP-conjugated secondary antibodies
(Santa Cruz Biotechnology) were applied to the membranes
at a 1:1000–4000 dilution for 1 hr. For the laminin overlay
assay, nitrocellulose membranes (Bio-Rad) were blocked
with laminin overlay buffer (10 mM ethanolamine, 140 mM
NaCl, 1 mM MgCl2, and 1 mM CaCl2, pH 7.4) containing
5% nonfat dry milk for 1 hr at 4C followed by incubation
with laminin from Engelbreth-Holm-Swarm murine sarcoma
basement membrane (Sigma) at a 1:500 dilution overnight at
4C in laminin overlay buffer. Membranes were washed and
incubated with rabbit antilaminin antibody (Sigma) at a
1:1500 dilution followed by antirabbit HRP-conjugated sec-
ondary antibody (Santa Cruz Biotechnology) applied at a
1:3000 dilution. All blots were developed by electro-
chemiluminescence (ECL) immunodetection (PerkinElmer,
Waltham, MA), exposed to BioMax Light film (Sigma),
and processed by an LAS-4000 imaging system (Fujifilm,
Valhalla, NY).
Results
AAV vector construction and gene expression in vitro
AAV vectors were generated for the expression of
LARGE (AAV9-LARGE) or FKRP (AAV9-FKRP). The
full-length human LARGE or FKRP coding sequence was
optimized for high expression in a mouse model. The re-
sulting construct was subcloned into an AAV9 vector under
control of a CB promoter and CMV enhancer. AAV9 was
chosen because it has been shown to have widespread
transduction in multiple tissues, including skeletal and car-
diac muscles (Inagaki et al., 2006; Pacak et al., 2006).
AAV-mediated LARGE expression was initially exam-
ined in mouse C2C12 myoblasts and myotubes by immu-
nohistochemical analysis. Transduced C2C12 cultures were
labeled with antibodies to LARGE and the Myc epitope—
with the Myc-specific monoclonal antibody 9E10 (Evan
et al., 1985). LARGE expression was visualized as punc-
tuated signals regularly distributed throughout the cyto-
plasm and along the edges of the nuclei (Supplementary Fig.
S2). The expression of LARGE increased throughout the
differentiation of C2C12 myoblasts into myotubes, consis-
tent with a higher infection efficiency to myotubes utilizing
AAV. In transduced myotubes, the Myc tag also showed
colocalization with GM130—a cis-Golgi matrix protein
(Supplementary Fig. S2), confirming the localization of
LARGE in the Golgi apparatus (Brockington et al., 2005;
Grewal et al., 2005). The same series of experiments was
carried out for AAV9-mediated FKRP expression, eluci-
dating similar results reported previously (Xu et al., 2013)
(Supplementary Fig. S3).
To investigate whether LARGE overexpression was able
to alter glycosylation of a-DG, we conducted Western blot
analysis on C2C12 differentiated myotubes (Supplementary
Fig. S2) using the IIH6C4 antibody—which recognizes the
ligand-binding carbohydrate epitope of a-DG (Campanelli
et al., 1994; Gee et al., 1994). Immunoblots detected gly-
cosylated a-DG as a broad band with a molecular weight of
150–300 kDa in AAV9-LARGE-treated cultures. In con-
trast, only a single narrow band with a molecular weight of
about 170 kDa was observed in the same cells without AAV
transfection. These results confirm the AAV9-mediated
LARGE overexpression and its effect of hyperglycosylation
on a-DG.
LARGE expression restores functional glycosylation
of a-DG in muscle of Largemyd mice
Next, we examined LARGE expression in vivo using the
Largemyd mouse model. Largemyd mice possess a sponta-
neous deletion of exons 5–7 of the gene (in front of the
catalytic domains), which causes a frame-shift and a pre-
mature stop codon, leading to a loss of function and a severe
muscle pathology (Grewal et al., 2005). AAV9-LARGE
(5 · 1010 vector genomes/ml) was administered via intra-
muscular injection to the tibialis anterior muscles of the
mice (3 months of age). Immunohistochemistry was unable
to detect endogenous LARGE expression with the LARGE
(Y-14) antibody against the C-terminus of human LARGE
in the untreated Largemyd muscles (Fig. 1A). As expected,
functional glycosylation of a-DG was also undetectable in
the untreated Largemyd muscles using the IIH6C4 antibody
(Fig. 1A). In contrast, muscles of the Largemyd mice treated
with the AAV9-LARGE showed strong signals for LARGE
expression, as indicated by punctuated dots distributed
throughout the sarcoplasm and along the sarcolemma (Fig.
1A). Immunohistochemistry also confirmed functionally
glycosylated a-DG with the IIH6C4 antibody in the AAV9-
LARGE-treated muscle fibers (Fig. 1A). The coexpression
of the LARGE and IIH6C4 epitopes in the same fibers was
confirmed by the staining of serial sections (Fig. 1A). The
signal intensity for both antibodies suggests that a strong
expression of LARGE correlates positively with a strong
expression of the IIH6C4 epitope.
Western blot analysis using the IIH6C4 antibody (Fig.
1B) showed that the AAV9-LARGE-treated muscle pro-
duced positive signals representing heavily glycosylated
forms ( ‡ 200 kDa) of a-DG, which were significantly larger
than that detected in the same muscle type of the control
(wild-type) sample (*160 kDa). As expected, IIH6C4 im-
munoreactivity was undetectable in the untreated Largemyd
sample. The detection of b-DG confirmed that a similar
amount of protein was loaded for each sample. Collectively,
these results show that LARGE overexpression can result in
hyperglycosylation of a-DG in Largemyd mice.
LARGE generates functional a-DG in FKRPP448L mice
We next investigated whether the overexpression of
LARGE could also rescue the functional defects of the pu-
tative glycosyltransferase FKRP—a hypothesis proposed by
Dr. Campbell’s group (Barresi et al., 2004). For these ex-
periments, we used the mouse model containing a knock-in
proline-to-leucine missense mutation in the FKRP gene
(FKRPP448L). This model revealed moderate skeletal muscle
dystrophic phenotypes from as early as 2–3 weeks, but
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lacked clear histological defects in the central nervous
system along with normal breeding activity and a near-
normal life span (Blaeser et al., 2013).
The AAV9-LARGE vector was intraperitoneally injected
into the FKRPP448L mice (5 weeks of age) with a single dose
of 4 · 1010 viral genomes per gram body weight, and its
effect was examined 5 weeks postinjection. Immuno-
histochemical staining revealed LARGE expression in the
heart, diaphragm, and skeletal muscles (Fig. 2A). Fluores-
cence signals as punctuated dots, similar to that observed in
the skeletal muscle of Largemyd mouse, were observed
within the sarcoplasm and often concentrated at the sarco-
lemma with regular spacing in the majority of muscle fibers.
The levels of LARGE varied considerably from fiber-to-
fiber within the same muscles; there were very few fibers
with signals fused into big patches within the sarcoplasm,
and a portion of fibers remained negative for LARGE ex-
pression, suggesting partial transduction of the AAV9-
LARGE vector with the current dosage or vector system. To
determine whether AAV9-LARGE expression could gen-
erate functional a-DG, we tested the IIH6C4 immunoreac-
tivity of the transduced tissues (Fig. 2A). Approximately
50% or more fibers in all the muscle examined were de-
tected with positive signal by the antibody with the lowest
percentage of positive fibers in the tibialis anterior and the
highest in cardiac muscle (70–80%). This was in high
contrast to the untreated FKRPP448L tissues, where only a
few (maximum of 15%) tibialis anterior muscle fibers
spontaneously expressed glycosylated a-DG, most of them
with weak signal (Supplementary Fig. S4). This suggests
that LARGE overexpression was able to restore functional
glycosylation of a-DG in FKRP mutant muscles. This is
further supported by the fact that almost all fibers expressing
LARGE showed clearly detectable restoration of function-
ally glycosylated a-DG, and the levels of the two proteins
are well correlated, although variation in signal intensity
existed. Most fibers without a detectable signal for LARGE
were also negative for IIH6C4 antibody staining, indicating
that there may exist some threshold levels of LARGE ex-
pression that are required to restore detectable levels of
glycosylated a-DG. As expected, there was a strong IIH6C4
signal for all tissues in the wild-type mice (Supplementary
Fig. S4). Laminin expression (pan-laminin and laminin a2)
was detected in muscles of all mice groups (Supplementary
Fig. S5). The signals for both laminin antibodies were ho-
mogenous in wild-type muscles with the intensity similar to
that detected in the majority of muscle fibers of the
FKRPP448L mice with or without AAV9-LARGE treatment.
However, clearly stronger signals were observed in small-
caliber and mostly centrally nucleated (regenerating) fibers,
but this was the case for both AAV9-LARGE-treated and
untreated FKRPP448L tissues, although the number of such
fibers are smaller in the treated than in untreated muscles.
These results therefore suggest that stronger laminin a2
expression is related to the process of muscle regeneration
rather than LARGE overexpression in our model system.
Transgene LARGE expression was also confirmed by
Western blot analysis with the LARGE (Y-14) antibody
(Fig. 2B). Positive signals were detected only in the AAV9-
LARGE-treated FKRPP448L mice, with much higher signals
in the heart and diaphragm than in the tibialis anterior. This
is likely because of the high tropism of the AAV9 to cardiac
muscle and the route of intraperitoneal injection (to dia-
phragm). Restoration of functionally glycosylated a-DG in
the heart, diaphragm, and other skeletal muscles was also
confirmed by Western blot analysis (Fig. 2B). Positive sig-
nals were hardly detectable in the cardiac muscle, and at
very low levels in the diaphragm and tibialis anterior mus-
cles of the untreated FKRPP448L mice when compared with
the normal (wild-type) muscles. Conversely, the AAV9-
LARGE-treated FKRPP448L mice samples demonstrated a
dramatic increase in IIH6C4 signals as broader molecular
FIG. 1. LARGE expression and rescue of functional a-DG in skeletal muscle of Largemyd mouse administered by
intramuscular injection. (A) Immunohistochemistry of tibialis anterior muscle sections either untreated (top) or treated with
AAV9-LARGE (bottom). LARGE expression was detected with LARGE (Y-14) for the untreated or Myc tag for the
treated. Functional a-DG was detected with IIH6C4 antibody. Green or red signals indicate positive signals. Asterisks
indicate the same fiber in serial sections. Cellular nuclei were counterstained with DAPI (blue). Scale bar: 50 lm. (B)
Western blot analysis of protein lysates from skeletal muscle sections either untreated ( - ) or treated ( + ) with AAV9-
LARGE using IIH6C4 and b-DG antibodies. AAV, adeno-associated virus; a-DG, a-dystroglycan. Color images available
online at www.liebertpub.com/hgtb
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weight bands with size ranges similar to and significantly
larger than that in wild-type tissues, indicating the expres-
sion of variably hyperglycosylated a-DG species. The la-
minin overlay assay (Fig. 2B), showed broader bands with
molecular weights similar to that detected by the IIH6C4
antibody in the AAV9-LARGE-treated FKRPP448L muscles.
Conversely, the laminin-binding activity of a-DG was
nearly undetectable in the untreated FKRPP448L tissues. As
expected, b-DG immunoreactivity was similar for all sam-
ples (Fig. 2B).
The pathology of the AAV9-LARGE-treated FKRPP448L
mice improved after the 5-week treatment as compared with
the untreated mice. As evident from the H&E staining (Fig.
3A), large areas of degeneration commonly observed in
untreated FKRPP448L mice became only occasionally de-
tected in the AAV9-LARGE-treated mice. There was a
significant reduction in the number of small-caliber re-
generating fibers, especially in the diaphragm and the ti-
bialis anterior muscles (Fig. 3A). The overall percentage of
centralized nucleation was reduced to 23.5 – 9.4% in skel-
etal muscles of the treated tibialis anterior muscles compared
with 53.6 – 3.6% in untreated muscles (statistically signifi-
cant). The improvement in pathology with the LARGE ex-
pression was also reflected by the fiber size distribution (Fig.
3B). The FKRPP448L untreated mice showed more variability
in fiber size than the AAV9-LARGE-treated FKRPP448L
mice. Histology in the heart was undistinguishable between
the two groups with only small areas of increased interstitial
tissue present in both AAV9-LARGE-treated and FKRPP448L
untreated mice (Fig. 3A). Likewise, the difference in creatine
kinase levels was not significant between the cohorts,
3958 – 1868 (U/L) in the AAV9-LARGE-treated FKRPP448L
mice and 3961 – 1504 (U/L) in the untreated FKRPP448L
mice.
FKRP overexpression is unable to restore functional
glycosylation of a-DG in Largemyd mice
We have previously constructed an AAV9-FKRP re-
combinant vector expressing wild-type codon-optimized
FKRP (Xu et al., 2013). Local and systemic delivery of
AAV9-FKRP mediated effective expression of FKRP in
both skeletal and, more notably, cardiac muscle of the
FKRPP448L mutant mice. To examine if FKRP over-
expression has any effect on the functional glycosylation of
a-DG in the Largemyd mice (3 months of age), the AAV9-
FKRP vector was administered via intraperitoneal injection,
and the effect was examined 5 weeks postinjection. Ex-
pression of FKRP in Largemyd mice was clearly detected in
all tissues examined, including the heart, diaphragm, and
tibialis anterior muscles by immunostaining with the FKRP-
STEM antibody (Fig. 4A). The distribution of FKRP ex-
pression in the Largemyd mouse was similar to that of the
LARGE expression in the FKRPP448L mice described above.
As expected, there was no signal detection in untreated mice
(data not shown). Conversely, functionally glycosylated a-
DG was undetectable by the IIH6C4 antibody in any fiber
clearly expressing FKRP (Fig. 4A). Western blot analysis
confirmed these findings and showed that there was no
correlation between levels of FKRP expression and rescue
of functional a-DG (Fig. 4B). As a control, functional gly-
cosylation of a-DG was restored in skeletal muscles of the
FKRPP448L mouse with the same batch of AAV9-FKRP
(Supplementary Fig. S6). Histologically, the percentage of
centrally nucleated fibers was similar between the AAV9-
FKRP-treated (53.1 – 3.1%) and untreated (65.7 – 1.5%)
Largemyd tibialis anterior muscles and there was no signifi-
cant improvement in pathology with the FKRP expression
as reflected by the H&E staining and fiber size distribution
(Supplementary Fig. S7). Serum creatine kinase levels also
remained unaffected between the treated and untreated
Largemyd mice (data not shown).
FIG. 2. LARGE overexpression generates functional a-
DG in FKRPP448L mice. (A) Immunohistochemical staining
with Myc tag (green, left panel) or IIH6C4 (red, right panel)
antibodies for LARGE and functional a-DG, respectively.
Asterisks indicate the same fiber in serial sections. Cellular
nuclei were counterstained with DAPI (blue). Scale bar:
50 lm. (B) Western blot analysis of protein lysates from the
heart (H), diaphragm (D), and tibialis anterior (TA) using
IIH6C4, LARGE (Y-14), and b-DG antibodies and a lami-
nin overlay assay.
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FKRP forms a complex with LARGE
LARGE and FKRP are both known to modulate the
postphosphoryl modification of a-DG, and mutations in ei-
ther of the genes can result in the same defect in monoester-
linked phosphorylated a-DG. Our results show that both
proteins colocalized within the Golgi apparatus (Supple-
mentary Fig. S8). As a result, we speculate that the two
proteins might work in a complex for the completion of the
postphosphoryl modification of a-DG. To test this theory,
we examined the two proteins by immunoprecipitation (Fig.
5). Samples from cardiac muscle were chosen for tissue
analysis, mainly because previous reports revealed higher
transgene expression of LARGE in this tissue (Brockington
et al., 2010). However, because antibodies directed against
both proteins are ineffective in immunoprecipitating the
FIG. 3. Histopathology of the AAV9-LARGE-treated FKRPP448L tissues. (A) Hematoxylin and eosin staining of the heart,
diaphragm, and tibialis anterior tissues from AAV9-LARGE-treated FKRPP448L, untreated FKRPP448L, and wild-type (C57)
mice. Scale bar: 200 lm. (B) Fiber size distribution of tibialis anterior muscles from each experimental group (n = 3,
mean – SEM, Student’s t-test, *p < 0.05). Color images available online at www.liebertpub.com/hgtb
FIG. 4. Expression of FKRP and functionala-DG in Largemyd
mice after AAV9-FKRP treatment. (A) Immunohistochemical
staining of AAV9-FKRP-treated tissues with FKRP-STEM (red,
left panel) or IIH6C4 (green, right panel) antibodies. Asterisks
indicate the same fiber in serial sections. Cellular nuclei were
counterstained with DAPI (blue). Scale bar: 50 lm. (B) Western
blot analysis of protein lysates from the heart (H), diaphragm
(D), and tibialis anterior (TA) using IIH6C4, FKRP-STEM, and
b-DG antibodies. Asterisk indicates nonspecific bands observed
in all samples. Color images available online at www.liebert
pub.com/hgtb
FIG. 5. Immunoprecipitation for the detection of FKRP
and LARGE in cardiac muscle. Lanes were either treated
( + ) or untreated ( - ) with the respective vector, protein,
and/or antibody. Lane 1 (far left), void portion after im-
munoprecipitation; lane 2, immunoprecipitated portion; lane
3, AAV9-LARGE-infected tissue without immunoprecipi-
tation; lanes 4 and 5, void and immunoprecipitated portion
of control tissue, respectively; lane 6, whole tissue lysate of
the AAV9-FKRP-treated tissue.
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targeted protein, we were forced to use the c-Myc (rabbit
polyclonal) antibody for immunoprecipitation of vector-
expressed FKRP in FKRPP448L mice. Examination of the
immunoprecipitate by Western blot confirmed expression of
FKRP (Fig. 5). The same immunoprecipitate was re-probed
with LARGE (Y-14) antibody and showed a specific band of
approximately 88 kDa, matching the size of endogenous
LARGE (Fig. 5). It should be noted that this band was
nearly undetectable in the void portion of the tissue lysate or
in whole tissue lysate without immunoprecipitation. Overall,
these results support the notion that FKRP and LARGE are
likely parts of a protein complex working in collaboration,
although whether the two proteins contact directly or indi-
rectly has yet to be determined.
Discussion
Among the known genes involved in the functional gly-
cosylation of a-DG, LARGE has a different regulatory role
in a-DG glycosylation. This is most convincingly demon-
strated by the fact that overexpression of LARGE was able
to restore the functional glycosylation of a-DG not only in
cells with LARGE mutations, but also with FKTN and
POMGnT1 mutations in vitro and in vivo (Barresi et al.,
2004). However, overexpression of POMGnT1 was unable
to compensate for the loss of LARGE function. In this study,
we further demonstrated that LARGE overexpression is able
to rescue the functional defect of FKRP in the FKRPP448L
mouse, leading to the restoration of functional a-DG in
skeletal muscles as well as cardiac muscle. Furthermore, we
showed that, as the result of LARGE overexpression, dys-
trophic pathology of the mutant muscles was improved with
a significant reduction in the number of regenerating and
degenerating fibers. The number of centrally nucleated fi-
bers was also reduced when compared with the controls. In
contrast, overexpression of FKRP was unable to correct the
glycosylation defects and improve pathology in muscles of
the Largemyd mice. Our results further support the notion
that overexpression of LARGE could serve to rescue a wide
range of dystroglycanopathies caused by defects in a mul-
titude of genes, including FKRP.
To assess the efficacy of LARGE overexpression as a
viable gene therapy approach for dystroglycanopathies,
Muntoni’s group studied LARGE transgenic models in a
normal background and reported that overexpression of
LARGE induced hyperglycosylation of a-DG (Brockington
et al., 2010). The group also noticed that LARGE expression
in the heart was regionally confined and variable—only
approximately 25% of the cardiomyocytes showed positive
signal with predominantly transmural distribution in all
LARGE transgenic lines. Transgenic expression in the
cardiomyocytes correlated well with hyperglycosylation of
a-DG. Reasons for variable expression are not fully under-
stood, but the observation suggests potential difficulty in
inducing homogeneous vector-induced LARGE expression
in the target tissue. On the contrary, our short-term study
shows that the majority of cardiac muscle can be effectively
induced to express the LARGE transprotein, although with
considerable variation in expression levels. As a result,
functionally glycosylated a-DG was detected in the majority
of the cardiac muscle fibers, again with variation in signal
levels. Therefore, it is possible that the limited expression of
LARGE and associated hyperglycosylated a-DG in cardiac
muscle in transgenic models could be related to develop-
mental regulation specific to the LARGE transgene. The
difference in levels of LARGE expression between the
AAV9 vector and chromosomally located transgene could
also be a contributing factor.
While some available evidence thus far has clearly
demonstrated the potential of using LARGE as an effective
transgene to treat a broader range of dystroglycanopathies,
various potential concerns of LARGE overexpression have
been noted in the study of LARGE transgenics. LARGE
transgenic mice with a normal background tend to exhibit
normal development and muscle histology; however, the
aged LARGE transgenic mice show an increase in sus-
ceptibility to contraction-induced injury and a 30% decline
in force generation when compared with age-matched
controls (Brockington et al., 2010). More recently, Dr.
Brown’s group further reported that contrary to expecta-
tion, transgenic expression of LARGE in a dystrophic
mouse with FKRP mutations resulted in a worsening of the
muscle pathology, implying that any future strategies
based upon LARGE upregulation require careful manage-
ment (Whitmore et al., 2013). These results are apparently
in contradiction to the observation from the current study,
which showed a clear pathological benefit from the
LARGE-induced functional glycosylation of a-DG in FKRP
mutant mice. Both studies demonstrated the LARGE over-
expression in muscles, but the time of expression is different
and levels of expression cannot be compared. Therefore, the
detrimental effect of LARGE overexpression could be
limited to the transgenic model only. However, the current
study has only examined the effect of LARGE over-
expression for a short term, and as a result, a long-term ef-
ficacy study in adult FKRP mutant mice is required to
determine the potential of LARGE upregulation as gene
therapy for FKRP dystroglycanopathies.
Virus-mediated gene therapy has the advantage of sim-
plicity, because it may only require one treatment to achieve
long-lasting effects. However, it also creates difficulty in
establishing optimal levels of transgene expression. This
could be particularly important for LARGE as a therapeutic
transgene for dystroglycanopathies. LARGE overexpression
induced mainly abnormal glycosylation of a-DG, explicitly
characterized by a larger molecular mass. Currently, gly-
cosylated a-DG detected by IIH6C4 antibody is considered
to be the functional variant of the protein; however, it is
probable that glycosylated a-DG with larger molecular
weights could function differentially as a molecular bridge
between the cell membrane and extracellular proteins,
thereby providing different levels of protection for mem-
brane stability. We hypothesize that hyperglycosylated a-
DG could be less effective in providing protection and may
be related to the observed detrimental effect, especially
when the amount of functional glycan epitopes exceeds
certain levels. Because LARGE overexpression also pro-
duces glycosylated a-DG with a size similar to that of
normal (wild-type) muscles, optimal levels of LARGE
expression could be the key for achieving glycosylation of
a-DG with normal functions. Clearly, carefully designed
experiments are required to fully investigate these concerns.
In contrast, FKRP overexpression produces the functionally
glycosylated a-DG with the same size as those in normal
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muscles and thus less a concern if FKRP gene therapy is
considered for the FKRP-related dystroglycanopathies.
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